Ai Virtual Agent Selection, Implementation and Support Keys to Success
Improving Population Health via Non-traditional Partnerships
Efficient Data Management in the Healthcare Space
Transform Healthcare with a Passion for Innovation
Significant technological change often means a cultural shift for...
NovletMattis, Chief Information Officer, Orlando Health
Disrupting the CIO Comfort Zone to Innovate and Transform How...
Wes Williams, VP & CIO, Mental Health Center Of Denver
Bringing the Worlds of Technology and Health Closer to Each Other
Kristin Myers, Chief Information Officer, Mount Sinai Health System
The Biopsychosocial Model: The Future of Remote Patient Monitoring
Heather Comerci Reyes, Md, Me; Michael Hasselberg, Phd, Chief Digital Health Officer, University Of Rochester Medical Center
Thank you for Subscribing to CIO Applications Weekly Brief

Landing AI Announces Software Licensing Agreement with Ligand Pharmaceuticals Incorporated

The OmniAb antibody discovery platform provides Ligand's biopharmaceutical industry partners access to the world's most advanced antibody repertoires and screening technologies to enable unparalleled discovery of next-generation therapeutics.
Fremont, CA: Landing AI announced a software licensing agreement with Ligand Pharmaceuticals Incorporated to incorporate LandingLens into Ligand's OmniAb® and xPloration™ antibody discovery platforms. LandingLens is a software platform that provides an end-to-end workflow to build, iterate and operationalize AI-powered visual inspection solutions.
"Landing AI, under the leadership of world-renowned AI pioneer Andrew Ng, is a proven and trusted partner in empowering their customers to realize the business value of computer vision," says Bob Chen, Ph.D., Director, Systems Engineering with Ligand Pharmaceuticals. "We selected Landing AI because of the company's unique data-centric approach that puts getting high-quality data at the heart of AI development. Notably, the LandingLens software platform provides a host of specifically designed data preparation tools and capabilities that allow us to generate accurate and consistent datasets that we can iterate over time to continuously improve our existing AI systems."
The new AI-driven tools further improve Ligand's high-throughput single B cell screening accuracy and throughput in various complex biological assays, potentially increasing the yield of antibodies with desirable properties in even less time.
"AI and deep learning have emerged as powerful technologies to enable a variety of vision-based applications. We are excited to enter into this partnership with Ligand Pharmaceuticals and are committed to offering the best tools to help our customers unlock the promise of AI," said John Reuter, Vice President of Sales at Landing AI.
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Featured Vendors
-
Jason Vogel, Senior Director of Product Strategy & Development, Silver Wealth Technologies
James Brown, CEO, Smart Communications
Deepak Dube, Founder and CEO, Datanomers
Tory Hazard, CEO, Institutional Cash Distributors
Jean Jacques Borno, CFP®, Founder & CEO, 1787fp
-
Andrew Rudd, CEO, Advisor Software
Douglas Jones, Vice President Operations, NETSOL Technologies
Matt McCormick, CEO, AddOn Networks
Jeff Peters, President, and Co-Founder, Focalized Networks
Tom Jordan, VP, Financial Software Solutions, Digital Check Corp
Tracey Dunlap, Chief Experience Officer, Zenmonics